TScan Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Aug 12, 2024 and accepted by EDGAR at Aug 12, 2024, 07:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-04-01 to 2024-06-30 | $536.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2024-01-01 to 2024-06-30 | $1.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2024-04-01 to 2024-06-30 | $26.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-01-01 to 2024-06-30 | $51.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-04-01 to 2024-06-30 | −$34.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-01-01 to 2024-06-30 | −$65.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-04-01 to 2024-06-30 | $952.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2024-01-01 to 2024-06-30 | $1.9m | us-gaap:InterestExpense |
| Net income | 3 months2024-04-01 to 2024-06-30 | −$31.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-01-01 to 2024-06-30 | −$61.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-04-01 to 2024-06-30 | −$0.28 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-01-01 to 2024-06-30 | −$0.59 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-04-01 to 2024-06-30 | −$0.28 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-01-01 to 2024-06-30 | −$0.59 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-04-01 to 2024-06-30 | 113,425,357 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-01-01 to 2024-06-30 | 104,150,625 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-01-01 to 2024-06-30 | −$55.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-01-01 to 2024-06-30 | $1.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-06-30 | $242.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-06-30 | $299.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $374.9m | us-gaap:Assets |
| Current liabilities | At period end2024-06-30 | $38.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-06-30 | $119.7m | us-gaap:Liabilities |
| Long-term debt | At period end2024-06-30 | $20.1m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-06-30 | $10.3m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2024-06-30 | $255.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-095066. Last ingested by Listed: Oct 26, 2026, 08:08 ET. Listed shows no prices and gives no investment advice.